Fundraising Fox
Barinthusbio
NASDAQ: BRNS11 known investors
Find your way into Barinthusbio
Sign up to see every warm intro you have to Barinthusbio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Barinthusbio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies designed to guide T cells to treat autoimmune and inflammatory diseases. The company was formed from the 2021 merger of Vaccitech (an Oxford University spinout) and Avidea Technologies (a spinout from NIH and Johns Hopkins University).
Founders & leadership
Investors · 11
How we know: Future Planet Capital's portfolio page · funding news · futureplanetcapital.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Oxford Science Enterprises's portfolio page · Not right? Tell us
How we know: funding news · futureplanetcapital.com · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$168M disclosed across 1 round · 2021
- $168MSeries BMar 2021 · 4 sources
M&G Investment Management (lead), Future Planet Capital, Gilead Sciences, Monaco Constitutional Reserve Fund, Oxford Sciences Innovation, Tencent
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Barinthusbio do?
- Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies designed to guide T cells to treat autoimmune and inflammatory diseases. The company was formed from the 2021 merger of Vaccitech (an Oxford University spinout) and Avidea Technologies (a spinout from NIH and Johns Hopkins University).
- Who founded Barinthusbio?
- Barinthusbio was founded by Geoffrey Lynn.
- Who are Barinthusbio's investors?
- Barinthusbio's investors include Future Planet Capital, GV (Google Ventures), Oxford Science Enterprises, Gilead Sciences, Korea Investment Partners, Milltrust International Group, Tencent Holdings, Xfund.
- How much funding has Barinthusbio raised?
- Barinthusbio has disclosed $168M raised across 1 round.